CALL US: 1-352-733-0111

A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg administered orally once daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk


The purpose of this research study is to : 1. Test the safety and effectiveness of treatment with two doses BI 10773 in subjects with Type 2 diabetes and high cardiovascular risk. 2. To compare BI 10773 to placebo (inactive substance) by assessing the number of Cardiovascular Event endpoints such as cardiovascular death, nonfatal stroke and nonfatal myocardial infarction. (Enrolling in Jacksonville, FL)


heart disease, type 2 diabetes

Principal Investigator

Kent Wehmeier, Clinical Associate Professor ( & Chief )



Contact Information

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at

Other Resources

  • Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams